Evidence map›Paper›PMID 32721533›Full record

SynthesisInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2020

Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis.

Yue Zhou, Qing Yang, Jingwei Chi, Bingzi Dong, Wenshan Lv, Liyan Shen, Yangang Wang

2 registry-linked trialsOpen access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 224 papers, 19 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
224citing papers in PubMed, 19 pooled it
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05102708 completednot on this mapstarted 2021, after this paper: background citation

Study of COVID-19 Prognostic Factors in Hospitalized Patients

TypeobservationalSponsorFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauRan2021 to 2022Enrolled3,725ConditionsCOVID-19ArmsPrognostic factors of severe COVID-19
NCT05305508 phase2completednot on this mapstarted 2022, after this paper: background citation

A Randomized, Placebo-controlled, Double-blind, Monocenter, Phase II Trial to Assess the Efficacy of Calcium Dobesilate (CaD) vs. Placebo on SARS-CoV-2 Viral Load Amongst Outpatients With COVID-19.

TypeinterventionalSponsorHervé SPECHBACHRan2022 to 2024Enrolled74ConditionsCOVID-19 Virus DiseaseArmsCalcium Dobesilate, Mannitol
3 · Its place in the literature

Who cites it

224 citing papers in PubMed, 19 syntheses or guidelines pooled it, 420 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Guideline
  16. Pooled it
  17. Serum amyloid A concentrations, COVID-19 severity and mortality: An updated systematic review and meta-analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021
    Pooled it
  18. Pooled it
  19. Pooled it
  20. Trial

164 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yue ZhouDepartment of Endocrinology, Affiliated Hospital of Medical College Qingdao University, Qingdao, China.
Qing YangInstitute of Biophysics, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Beijing, China.
Jingwei ChiDepartment of Endocrinology, Affiliated Hospital of Medical College Qingdao University, Qingdao, China.
Bingzi DongDepartment of Endocrinology, Affiliated Hospital of Medical College Qingdao University, Qingdao, China.
Wenshan LvDepartment of Endocrinology, Affiliated Hospital of Medical College Qingdao University, Qingdao, China.
Liyan ShenDepartment of Endocrinology, Affiliated Hospital of Medical College Qingdao University, Qingdao, China. Electronic address: sly1003@126.com.
Yangang WangDepartment of Endocrinology, Affiliated Hospital of Medical College Qingdao University, Qingdao, China. Electronic address: 15315620815@163.com.
Qingdao University · CNInstitute of Biophysics · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesExisting findings regarding the relationship between comorbidities and the severity of coronavirus disease 2019 (COVID-19) are inconsistent and insufficient. The aim of this study was to evaluate the association between different comorbidities and the severity of COVID-19.

methodsThe PubMed, Embase, and Cochrane Library databases were searched to identify studies reporting the rates of comorbidities in COVID-19 patients with severe/fatal outcomes. Subgroup analyses were conducted according to disease severity and the country of residence. Odds ratios (OR) with 95% confidence intervals (CI) were pooled using random-effects models.

resultsA total of 34 eligible studies were identified. In patients with severe/fatal COVID-19, the most prevalent chronic comorbidities were obesity (42%, 95% CI 34-49%) and hypertension (40%, 95% CI 35-45%), followed by diabetes (17%, 95% CI 15-20%), cardiovascular disease (13%, 95% CI 11-15%), respiratory disease (8%, 95% CI 6-10%), cerebrovascular disease (6%, 95% CI 4-8%), malignancy (4%, 95% CI 3-6%), kidney disease (3%, 95% CI 2-4%), and liver disease (2%, 95% CI 1-3%). In order of the prediction, the pooled ORs of the comorbidities in patients with severe or fatal COVID-19 when compared to patients with non-severe/fatal COVID-19 were as follows: chronic respiratory disease, OR 3.56 (95% CI 2.87-4.41); hypertension, OR 3.17 (95% CI 2.46-4.08); cardiovascular disease, OR 3.13 (95% CI 2.65-3.70); kidney disease, OR 3.02 (95% CI 2.23-4.08); cerebrovascular disease, OR 2.74 (95% CI 1.59-4.74); malignancy, OR 2.73 (95% CI 1.73-4.21); diabetes, OR 2.63 (95% CI 2.08-3.33); and obesity, OR 1.72 (95% CI 1.04-2.85). No correlation was observed between liver disease and COVID-19 aggravation (OR 1.54, 95% CI 0.95-2.49).

conclusionsChronic comorbidities, including obesity, hypertension, diabetes, cardiovascular disease, cerebrovascular disease, respiratory disease, kidney disease, and malignancy are clinical risk factors for a severe or fatal outcome associated with COVID-19, with obesity being the most prevalent and respiratory disease being the most strongly predictive. Knowledge of these risk factors could help clinicians better identify and manage the high-risk populations.

Indexed as

BetacoronavirusComorbidityCoronavirus InfectionsCOVID-19HumansPandemicsPneumonia, ViralSARS-CoV-2ComorbidityCOVID-19FatalityICU admissionSevere

Identifiers

PMID32721533
PMCPMC7381888
OpenAlexW3044595037

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.